Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar-Apr;11(3-4):E100-E104.
doi: 10.5489/cuaj.4016. Epub 2017 Mar 16.

Is testis-sparing surgery safe in small testicular masses? Results of a multicentre study

Affiliations

Is testis-sparing surgery safe in small testicular masses? Results of a multicentre study

Murat Keske et al. Can Urol Assoc J. 2017 Mar-Apr.

Abstract

Introduction: Our goal was to evaluate benign and malignant lesions and testicular intraepithelial neoplasia (TIN) in the neighbouring normal-appearing testis tissue in men who underwent radical orchiectomy for testicular mass with a pathologic tumour size of ≤3cm.

Methods: In this retrospective, multicentre study, data of 252 patients from 11 different institutions were included. Patients were divided into three groups based on tumour size: Group 1 (0-1 cm; n=35), Group 2 (1.1-2cm; n=99), and Group 3 (2.1-3 cm; n=118). Benign lesions and TIN were sought in the neighbouring testicular tissue and compared between groups.

Results: Mean patient age was 32.3 years. Benign lesions were reported in 54.3%, 33.3%, and 14.4% of Groups 1, 2, and 3, respectively (p<0.05 between groups). TIN was detected in 20%, 42.4%, and 41.5% of Groups 1, 2, and 3, respectively (p<0.05 for Group 1 vs. Groups 2 and 3; p>0.05 for Groups 2 vs. 3). Multifocality was detected in 8.6%, 4%, and 0% of Groups 1, 2, and 3, respectively (p<0.05 for both Group 1 vs. Group 3 and for Group 2 vs. Group 3; p>0.05 for Group 1 vs. Group 2). A tumour cutoff size of 1.5 cm was found to be significant for detecting benign tumour. TIN and multifocality rates were similar in patients with a tumour size of ≤1.5 vs. >1.5 cm (p>0.05).

Conclusions: Benign lesions and TIN in the neighbouring testis were significantly decreased and multifocality was increased in patients with a tumour mass size of ≤1 cm. Testis-sparing surgery should be performed with caution and a safety rim of normal tissue should also be excised.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of benign and malignant testicular tumours, testicular intraepithelial neoplasia (TIN) and multifocality in the neighbouring testis tissue (Group 1: tumour size ≤1 cm; Group 2: tumour size 1.1–2.0 cm; Group 3: tumour size 2.1–3.0 cm). P values for detecting benign and malignant testicular mass lesions between groups include Group 1 vs. Group 2, p=0.047; Group 1 vs. Group 3, p=0.000; and Group 2 vs. Group 3, p=0.002. P values for detecting TIN between groups include Group 1 vs. Group 2, p=0.031; Group 1 vs. Group 3, p=0.034; and Group 2 vs. Group 3, p=0.894. P values for detecting multifocality between groups include Group 1 vs. Group 2, p=0.337; Group 1 vs. Group 3, p=0.011; and Group 2 vs. Group3, p=0.042.
Fig. 2
Fig. 2
Percentage of benign, malignant testicular tumours, testicular intraepithelial neoplasia (TIN) and multifocality in the neighbouring testis tissue due to a tumour cutoff size of 1.5 cm (Group A: tumor size ≤1.5 cm; Group B: tumour size 1.6–3.0 cm). P values for detecting benign and malignant testicular mass lesions between groups include Group A vs. Group B, p=0.000. P values for detecting TIN between groups include Group A vs. Group B, p=0.069. P values for detecting multifocality between groups include Group A vs. Group B, p=0.012.

References

    1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21:1323–60. https://doi.org/10.1093/annonc/mdp530. - DOI - PubMed
    1. Engholm G, Ferlay J, Christensen N, et al. NORDCAN—a Nordic tool for cancer information, planning, quality control, and research. Acta Oncol. 2010;49:725–36. https://doi.org/10.3109/02841861003782017. - DOI - PubMed
    1. Klatte T, de Martino M, Arensmeier K, et al. Management and outcome of bilateral testicular germ cell tumours: A 25-year, single-centre experience. Int J Urol. 2008;15:821–6. https://doi.org/10.1111/j.1442-2042.2008.02107.x. - DOI - PubMed
    1. Heidenreich A, Weissbach L, Höltl W, et al. German Testicular Cancer Study Group. Organ-sparing surgery for malignant germ cell tumour of the testis. J Urol. 2001;166:2161–5. https://doi.org/10.1016/S0022-5347(05)65526-7. - DOI - PubMed
    1. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–68. https://doi.org/10.1016/j.eururo.2015.07.044. - DOI - PubMed

LinkOut - more resources